🔗 Share this article

Ministers and senior MPs have raised concerns that the United Kingdom's series of deals with the US administration are "fundamentally unstable." This stems from revelations that a so-called "milestone" deal on pharmaceutical tariffs, which pledges zero tariffs in exchange for the NHS paying more, lacks any detailed agreement beyond vague headline terms outlined by government press releases.

A Deal Without Detail

The US-UK pharmaceuticals agreement, described as a "generational" achievement, remains an "statement of intent" without a signed legal text. Observers point out that the public statements from the UK and US governments frame the deal in divergent terms. The British version emphasizes securing "zero per cent tariffs" as a unique achievement, while the American announcement dwells on the agreement for the NHS to pay significantly more for new medications.

"We face a genuine possibility that the UK government has agreed to terms to increase medicine costs in return for only a pledge from President Trump," commented David Henig, a trade expert. "It is documented he has a record of not following through on agreements."

Wider Concerns Amidst a Suspended Agreement

Anxieties have been amplified by Washington's move to suspend the major technology agreement, which was previously called "a generational step-change" in the bilateral relationship. The US pointed to a lack of progress from the UK on lowering trade barriers as the reason for the pause.

Additionally, concessions promised for British farmers as part of an May trade agreement have still not been formally signed off by the US, despite a imminent January deadline. "We have been informed that that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Behind the scenes, ministers have voiced worries that the government's agreements with the US are unstable and unpredictable. One minister was quoted as stating the series of agreements as "built on sand," while another described the situation as the "prevailing condition" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, argued: "Perhaps most shocking than the administration's tactics is the UK government's naive belief that his administration is a good faith actor. The NHS is of vital importance."

Government Downplays Risks, Points to Gains

Ministry sources have downplayed the risk of the US withdrawing from the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been lobbying for the agreement, desiring stability on imports and pricing, making it less abstract than the paused tech deal.

Officials acknowledge that volatility is inherent in dealing with the current US leadership. However, they maintain that the UK has achieved real benefits for businesses, such as reduced duties on automobiles compared to other nations. "The fact we have 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a concrete advantage," one official said.

Yet, delays have surfaced in implementing the broader trade deal. Promised access for British beef have yet to be finalized, and the pledge to "reduce steel tariffs to zero" has not been fulfilled, with tariffs fixed at 25%.

As negotiations continue, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.